Industry Wire 203

  1. Judge strikes down FTC noncompete ban nationwide.
  2. Massachusetts forces Steward to transfer remaining hospitals.
  3. Humana forks over $90M to settle whistleblower fraud allegations.
  4. Providence to add 2,000 staff at its IT hub in India.
  5. Healthcare layoff tracker – BCBSM eliminates 64 positions.
  6. McLaren Health Care hit by ransomware attack… again.
  7. Healthcare bankruptcies slow after five-year high in 2023.
  8. CMS provides $4M relief for thousands of No Surprises Act complaints
  9. Patient safety goals at U.S. News’ top hospitals.
  10. Nurses Association of Cape Cod Healthcare authorizes strike.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]